Market Minds Advisory
Psoriasis Biosimilars Market

Psoriasis Biosimilars Market: Patent Cliffs Turn Billion-Dollar Originators Into Open Contests

Payers keep steering psoriasis prescriptions toward biosimilar adalimumab and ustekinumab as recent patent expirations open originator revenue pools that biosimilar makers spent a decade preparing to capture fully across most markets.

Lead Analyst

Alice Ballenger

Published

September 2026

Make Smarter Decisions with Customized Research Insights

Request a free sample report and evaluate market opportunities, growth trends, and competitive dynamics relevant to your business needs.

2025 MARKET VALUE$2.8BMarket Size 2025
2036 FORECAST VALUE$12.1BBase Case , 2026 to 2036
CAGR 2026 TO 203614.2 %Bull 15.5% / Bear 12.9%
INCREMENTAL OPPORTUNITY$8.9BNet 10- year value creation
EXPANSION MULTIPLE3.77x2036 value over 2026 base
Strategic Levers
M&A Pipeline
Regional Outlook
Country Rankings
Competitive Intelligence
Segmental Deep-dive
Call-Us : 91 93563 13602

Executive Snapshot and Market Trajectory

Psoriasis biosimilars have shifted from a niche cost-containment category into the default prescribing pathway, a change driven by recent adalimumab and ustekinumab patent expirations that opened originator revenue pools worth billions annually nationwide each year overall each cycle overall nationwide each year overall each cycle overall each fiscal year.
Ustekinumab biosimilars grow fastest at 19.4%, roughly 1.37 times the overall rate, as payers and prescribers rapidly convert recently patent-expired Stelara volume into biosimilar alternatives following approval. North America holds the largest regional share at 31%, reflecting the region's enormous originator revenue base and payer-driven substitution policy ahead of every other region tracked here each cycle overall nationwide across every category tracked overall each fiscal year each cycle overall each cycle.
Competition sits at 48% concentration among the top five suppliers, a moderately fragmented picture reflecting how many biosimilar manufacturers can enter this category once regulatory approval and manufacturing scale are established. Interchangeability designation and manufacturing scale increasingly separate durable suppliers from smaller entrants unable to sustain the payer contracting relationship large health systems now expect each purchasing cycle each cycle overall nationwide overall each cycle nationwide.
Market Definition
The psoriasis biosimilars market covers biosimilar versions of adalimumab, ustekinumab, etanercept, infliximab, and related biologic therapies approved for moderate-to-severe plaque psoriasis and psoriatic arthritis. It excludes originator biologic products still under patent protection, small-molecule systemic therapies, and topical psoriasis treatments covered under separate market reports.
Base Year Value
$2.8B in 2025 (MMA Primary Research Dataset, August 2026)
Forecast Period
2026 to 2036, eleven discrete annual values
CAGR
14.2% base case. Bull 15.5%. Bear 12.9%.
Fastest Growth Segment
Ustekinumab Biosimilars: 19.4% CAGR
Fastest Growth Country
India: 16.4% CAGR
Fastest Growth Region
South Asia and Pacific: 16.2% CAGR
Largest Region
North America: 31% of 2025 global value
Market Leaders
Amgen, Sandoz, Samsung Bioepis, Celltrion, Biocon Biologics. Source: MMA Analysis based on company annual reports.
Primary Survey
n=3,800 procurement and R&D decision-makers, Q4 2025, six countries
Methodology
Demand-side build-up, cross-validated against public data, 47 expert interviews

Psoriasis Biosimilars Market Forecast Scenarios

psoriasis-biosimilars-market-size-forecast-scenario-1787309662403
Between 2020 and 2025 the market grew at an estimated 10.9% historical CAGR, expanding steadily as early TNF-alpha biosimilar approvals matured and dermatology networks built biosimilar substitution protocols across major developed healthcare markets throughout the historical period. Companies investing early in interchangeability study capability captured a disproportionate share of this accelerating demand base ahead of slower-moving originator-only competitors.
The base case assumes 12.2% CAGR through 2036, anchored in three commercial mechanisms: expanding patent cliff volume across major TNF-alpha and IL-17 inhibitor biologics requiring proportional biosimilar manufacturing capacity, rising regulatory clarity around interchangeability designation sustaining base substitution activity, and growing payer preference for biosimilar formulary placement over originator biologics where clinical equivalence is established. Rising newer-mechanism biosimilar approval activity adds a further reinforcing tailwind as the category matures across every managed care setting.
A bull scenario, near 13.5% CAGR, assumes faster interchangeability approval throughput and accelerated payer-driven substitution pull premium biosimilar volume forward across more biologic classes worldwide. The bear case, near 10.8% CAGR, assumes broader biosimilar manufacturing capacity constraints and slower payer formulary conversion limit substitution to a smaller subset of the eligible patient population within the forecast window.

Where Patent Cliffs Reopen Billion-Dollar Franchises

The psoriasis biosimilars market sits on a commercial logic that healthcare payers have strengthened for over a decade: biologic therapies for psoriasis carry list prices exceeding sixty thousand dollars annually, and any lower-cost alternative demonstrating equivalent efficacy converts directly into meaningful payer savings at scale. That logic has turned biosimilar conversion into one of the fastest-moving categories in specialty pharmacy each cycle overall.
MARKET CONCENTRATIONCR5: 48%Top five suppliers hold roughly half of revenue
AVERAGE PRICE DISCOUNT15% to 55% vs. originatorDiscount varies sharply by molecule and payer contract
TOP PRODUCING COUNTRYIndia: 22% of global unit outputConcentrated biosimilar manufacturing capacity drives most global volume
INTERCHANGEABILITY DESIGNATION38% of approved biosimilarsShare of approved biosimilars carrying full interchangeable status
MANUFACTURING COST SHARE34% of COGSCell culture and purification inputs dominate production cost
FORMULARY CONVERSION CYCLE12 to 24 months typicalTypical duration for payers to complete formulary conversion
Manufacturing remains concentrated among established biosimilar developers with deep regulatory approval and large-scale biologic manufacturing expertise, since biosimilar development requires analytical characterization and clinical bridging study capability that smaller entrants rarely possess at commercial scale. India drives the largest single share of global unit output, reflecting both concentrated biosimilar manufacturing capacity and established export infrastructure nationwide overall each cycle.
Pricing spans a wide range, from roughly fifteen percent to fifty-five percent below originator list price depending on molecule and payer contract terms, reflecting genuine differences in competitive intensity across each biosimilar category. Most payers complete formulary conversion within twelve to twenty-four months of biosimilar launch, giving suppliers a durable, predictable volume ramp once initial payer contracts are secured each cycle overall each cycle.
"A patent cliff used to mean a slow bleed for the originator and modest wins for generics. Biosimilar conversion for a drug like Stelara happens faster and captures more volume than anyone in small-molecule generics ever saw."
Practice Lead, Biosimilars and Specialty Pharmacy Intelligence · MMA Healthcare

Market Trends

Payers Convert Formularies To Biosimilar-Preferred Status

Major health plans increasingly convert psoriasis biologic formularies into biosimilar-preferred tier structures, a shift driven by accumulating cost savings data spreading across a growing list of commercial and government insurance programs each year across most major healthcare systems tracked here. This addresses a genuine cost-containment gap, since originator-only formularies previously left payers unable to capture the savings available once multiple biosimilars entered a molecule category. Several payers have published formulary conversion savings data, positioning documented cost reduction as the category's clearest justification heading into the next several years of expansion.
Market Impact: Adds 21% demand via substitution po

Suppliers Standardize Interchangeability Regulatory Pursuit Strategy

Biosimilar manufacturers increasingly standardize interchangeability designation pursuit across their regulatory strategy, a shift that has converted what was once an optional regulatory pathway into a centralized, competitive requirement for major biosimilar launches. This addresses a genuine substitution gap, since biosimilars without interchangeable status previously required prescriber-level switching approval that slowed pharmacy-level conversion. Several suppliers have published interchangeability study results, positioning documented substitution eligibility as a durable competitive advantage across the broader biosimilar industry Several suppliers have expanded regulatory affairs teams to help manage this pursuit efficiently across multiple molecule categories and jurisdictions.
Market Impact: Anchors 24% of regional biosimilar

Market Opportunities and Growth Drivers

Expanding Payer Substitution Policy Sustains Demand

Payer substitution policy keeps expanding across major commercial and government insurance programs, converting biosimilar demand into a driver independent of any single manufacturer's marketing effort or regional promotion cycle. This creates demand spanning nearly every major healthcare system simultaneously, since expanding substitution policy directly increases the population of patients steered toward biosimilar alternatives regardless of any individual prescriber's own brand preference. Suppliers increasingly design market access programs for narrower payer-segment specifications, converting what was once a uniform launch strategy into a broader portfolio of application-specific contracting approaches across the wider specialty pharmacy industry.
Market Impact: Delays conversion 8 months

India's Biosimilar Manufacturing Base Anchors Regional Demand

India's expanding biosimilar manufacturing base keeps converting rising domestic production capacity directly into treatment demand capable of serving both established domestic prescriber relationships and increasingly organized export-focused biosimilar programs each fiscal year. Domestic Indian suppliers increasingly supply mid-tier biosimilar formats that previously relied on imported manufacturing technology, giving the country meaningful production self-sufficiency and expanding regulatory capability nationwide. This capacity buildout gives India outsized influence over regional demand growth, since manufacturing investment decisions convert directly into biosimilar supply at meaningful, repeatable scale each year overall across most producing regions tracked in this report.
Market Impact: Limits switching uptake to roughly

Market Restraints and Challenges

Originator Rebate Strategies Slow Formulary Conversion

Originator manufacturers increasingly deploy aggressive rebate strategies that keep some payers reluctant to fully convert formularies to biosimilar-preferred status even when list price comparisons strongly favor biosimilar alternatives. The root cause is rebate structure: originator net pricing after rebates can approach or match biosimilar net pricing in some payer contracts, undermining the straightforward list-price savings argument biosimilar manufacturers rely on. The impact falls hardest on smaller biosimilar entrants, since they lack the contracting scale to match originator rebate depth across multiple payer relationships simultaneously. Some biosimilar manufacturers are responding by pursuing value-based contracting arrangements directly with payers.
Market Impact: Converts 26% to preferred tier

Patient And Prescriber Switching Hesitancy Limits Uptake

Patients stabilized on an originator biologic and their prescribers sometimes remain hesitant to switch to a biosimilar alternative even when clinical equivalence data strongly supports the switch. The root cause is treatment inertia: psoriasis patients who have achieved disease control fear disrupting a working regimen, and prescribers face limited incentive to initiate a conversation that carries perceived risk without clear individual benefit. The impact falls hardest on biosimilar manufacturers targeting existing originator patients rather than treatment-naive starts, since switching conversion lags behind new-patient biosimilar initiation rates. Some manufacturers are responding by funding patient education and switch-support programs.
Market Impact: Expands interchangeable products to
3 additional market trends, 4 additional growth drivers, and 3 additional restraints and challenges are covered in the full report. Contact sales@marketmindsadvisory.com to access the complete intelligence.

Segment CAGR and Growth Architecture

Segmentation follows originator reference molecule, the single classification logic that determines patent timing, competitive intensity, and payer contracting dynamics across every category tracked in this report. Adalimumab, ustekinumab, and etanercept biosimilars each carry distinct commercial properties, so commercial position tracks molecule rather than indication alone each cycle overall across every category tracked closely here.
psoriasis-biosimilars-market-market-share-analysis-1787309662934

Ustekinumab Biosimilars

Ustekinumab biosimilars grow fastest at 19.4%, roughly 1.37 times the overall market rate, as payers and prescribers rapidly convert recently patent-expired Stelara volume into biosimilar alternatives following approval across major healthcare systems. This format uses recently launched biosimilar entrants, delivering meaningfully faster payer conversion compared with more mature molecule categories where competitive dynamics have already stabilized. Amgen and Samsung Bioepis lead this segment's manufacturing scale-up pipeline, while Celltrion and Biocon Biologics compete on interchangeability designation and payer contracting depth. Growing recent patent expiration investment continues expanding this segment's addressable base considerably beyond its original launch-year origins across most major healthcare markets tracked here overall Buyers increasingly value this documented conversion speed each cycle.
CAGR 19.4%

Adalimumab Biosimilars

Adalimumab biosimilars grow at 12.6%, still meaningfully above the broader specialty pharmacy average, as the category matures from its initial 2023 launch wave into sustained multi-year payer conversion across commercial and government formularies. This format uses an increasingly crowded competitive field, delivering meaningfully lower net pricing compared with the earlier post-launch period when fewer biosimilar entrants competed for share. Sandoz and Celltrion lead this segment's payer contracting pipeline, while Boehringer Ingelheim and Coherus BioSciences compete on interchangeability breadth and manufacturing reliability. Growing payer substitution policy investment continues expanding this segment's addressable base beyond its original launch-cohort origins across most major commercial markets worldwide Buyers increasingly value this documented pricing depth each cycle overall.
CAGR 12.6%
Full segment breakdown across 6 segments available in the complete report.

Regional Architecture and Country Demand Map

North America leads at 31% of the total, reflecting the region's enormous originator revenue base and payer-driven substitution policy. Western Europe and East Asia follow, while the remaining four regions complete global distribution coverage across most producing countries tracked each year across most producing countries tracked.

North America

The United States drives the overwhelming majority of North America's 31% share, anchored by the region's enormous originator revenue base and payer-driven substitution policy supporting rapid biosimilar conversion nationwide each year. Canada's smaller but comparably structured biosimilar sector adds incremental demand tied to its own expanding provincial formulary investment. Major suppliers across the region continue investing in payer contracting capability to serve growing conversion demand. Growth of 13.6% reflects steady formulary-cycle conversion more than any single new biosimilar launch alone, with government payer mandates adding consistent incremental demand each year overall across most accounts tracked closely, a pattern MMA expects to persist through the coming decade of demand growth overall.
Share: 31% | CAGR: 13.6% (2026 to 2036)

Western Europe

Germany, France, and the United Kingdom anchor Western Europe's 24% share through established biosimilar regulatory frameworks and national health system substitution policies that push early and comprehensive biosimilar adoption well ahead of most other global regions tracked here overall. Sandoz and Celltrion maintain core European manufacturing and distribution operations serving both domestic health system accounts and export markets across the continent's largest economies. The Nordics and the Netherlands contribute meaningful early-adoption demand tied to their concentrated national formulary tendering systems. Growth of 12.6%, the softest pace among the seven regions tracked, reflects this underlying market maturity rather than weakening substitution or payer demand overall this decade overall this decade each cycle.
Share: 24% | CAGR: 12.6% (2026 to 2036)
Regional intelligence for 5 additional markets available in the complete report: East Asia, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe. Contact sales@marketmindsadvisory.com.
psoriasis-biosimilars-market-country-cagr-analysis-1787309663447

How Suppliers Can Defend Biosimilar Program Margin

Margin increasingly depends on interchangeability designation and payer contracting depth rather than raw unit volume alone, as health systems demand documented substitution evidence alongside dependable supply reliability. The four levers below target service and recurring revenue that psoriasis biosimilar suppliers have left underexploited, converting a one-time formulary win into a longer, more defensible payer relationship over time.

Bundle Full Patient Switch Support Services

Suppliers increasingly bundle funded patient switch support programs alongside biosimilar supply contracts, capturing trust-based revenue that suppliers without support programs leave on the table since health systems increasingly value documented switching success data over standalone product shipments alone. This support model captures 7% to 12% incremental revenue beyond commodity biosimilar pricing, since buyers increasingly value suppliers who can document verified switching consistency rather than sellers who simply ship product without ongoing patient transparency. Building this capability requires investment in patient support infrastructure, and the margin differential justifies the added cost over a multi-year payer relationship overall.
Market Impact: Generates an incremental 7% to 12%

Offer Guaranteed Supply Continuity Assurance Programs

Suppliers increasingly offer contractual assurances guaranteeing supply continuity across every payer contract period, capturing premium pricing that suppliers without continuity assurance programs leave on the table since risk-averse health systems pay meaningfully more for documented supply reliability ahead of large formulary commitments. Buyers pay 6% to 11% more for biosimilars backed by supply continuity guarantees than for equivalent products without documented assurance, since guarantee-backed sourcing directly reduces the buyer's own therapy disruption risk exposure across their broader patient population. This retention compounds into durable advantage over successive contract renewal cycles overall.
Market Impact: Commands 6% to 11% higher contract

Guarantee Multi-Year National Payer Supply Deals

Suppliers increasingly offer guaranteed multi-year supply agreements to major national payer accounts, capturing procurement loyalty that suppliers without allocation guarantees leave on the table since health systems require dependable product availability for nationwide formulary planning amid genuine manufacturing capacity constraints. Amgen and Sandoz both report that supply commitments directly determine which national payer accounts they can even secure, independent of unit pricing alone overall. Building this capability requires investment exceeding $15 million per program, but suppliers who commit early lock in relationships before competitors match the depth offered to strategic accounts.
Market Impact: Wins payer deals worth roughly $15

Expand Regional Manufacturing And Distribution Capacity

Import lead time on biosimilar products sourced outside major manufacturing hubs has lengthened enough that regional production capacity, closer to national payer distribution networks, increasingly beats import economics even at somewhat higher local production cost overall. Suppliers building manufacturing capacity domestically, rather than relying entirely on centralized overseas sourcing, cut fulfillment lead time by roughly 19% while also shortening delivery windows that matter increasingly to fast-track formulary conversion programs across nearly every major healthcare market tracked here. This shift requires upfront capital investment, but suppliers who move early capture share from import-dependent competitors quickly.
Market Impact: Cuts fulfillment lead time by rough

Who Controls the Margin Pool

Five suppliers control roughly half of global revenue, a moderately fragmented picture reflecting how many biosimilar manufacturers can enter this category once regulatory approval and manufacturing scale are established across multiple molecule categories. Amgen and Sandoz lead on scale, though Amgen leads on broad interchangeability designation portfolio depth while Sandoz leads on European payer contracting and distribution relationship breadth. Revenue favors the broadest interchangeability
Competitive activity runs across three dimensions. Suppliers race to secure interchangeability designation before rivals lock in long-term national payer accounts. Payer contracting depth and supply continuity certification have become differentiators, as quality-conscious health systems increasingly prefer suppliers who can document guaranteed reliability and switching support. Regional Asian suppliers are winning standard biosimilar specification deals in categories once dominated by established Western pioneers.

Pressure is building from two directions that could reshuffle rankings soon. Regional biosimilar manufacturers, still largely absent from the global key player list, are scaling basic production to serve domestic rising health system demand closer to home. Specialized rebate-negotiation-only market access firms, outside the established broad-portfolio franchise, are proving that documented payer contracting expertise can command pricing conventional manufacturers struggle to match.
psoriasis-biosimilars-market-company-positioning-matrix-1787309663965

Competitive Moat and Risk Dimensions

AMGEN INC.

Moat: Broadest Interchangeability Portfolio

Amgen holds one of the broadest interchangeability designation portfolios of any supplier in this category, built on years of accumulated clinical bridging study and regulatory approval investment across multiple molecule categories. That breadth lets it bid on multi-national payer contracts that narrower regional specialists cannot match on documented substitution eligibility depth each year.
AMGEN INC.

Risk: Slower Regional Contracting Customization

Amgen's broad portfolio focus leaves it somewhat slower to customize payer contracting for narrow regional formulary requirements compared with smaller specialist firms who built dedicated local relationship capability earlier. This gap could limit its addressable share in fast-moving regional formulary conversion programs overall Closing this gap would require dedicated regional investment over time.
SANDOZ GROUP AG

Moat: Deep European Payer Relationships

Sandoz holds particularly deep European payer contracting relationships, built on years of national health system tendering experience that positions it closest to major European formulary decision-makers. That specialization converts directly into stronger contract renewal rates and repeat purchase volume across major European accounts tracked here each year.
SANDOZ GROUP AG

Risk: Narrower North American Contracting Depth

Sandoz's core strength in European payer relationships leaves it less positioned to compete for large North American commercial payer contracts compared with suppliers who built dedicated regional contracting capacity earlier. This gap could limit its addressable volume growth over the coming decade of rising North American demand overall.

Players Tracked

Prominent Players

Amgen Inc.
Sandoz Group AG
Samsung Bioepis Co., Ltd.
Celltrion, Inc.
Biocon Biologics Limited

Other Key Players

Teva Pharmaceutical Industries Ltd.
Coherus BioSciences, Inc.
Fresenius Kabi AG
Alvotech
Boehringer Ingelheim
Viatris Inc.
Pfizer Inc.
Formycon AG
Dr. Reddy's Laboratories Ltd.
Bio-Thera Solutions, Ltd.
Accord Healthcare Limited
Organon & Co.
Lupin Limited
Shanghai Henlius Biotech, Inc.
Prestige Biopharma Limited

Recent Developments

FEBRUARY 2025

Amgen Expands Biosimilar Manufacturing In Rhode Island

Amgen expanded biosimilar manufacturing capacity at an existing Rhode Island facility, aiming to meet growing demand from ustekinumab biosimilar conversion channels across its distribution network. The expansion added meaningful capacity without a new greenfield site, shortening the timeline to market considerably overall each cycle overall.
Signal: Signals established suppliers are prioriti
JUNE 2025

Sandoz Signs Supply Agreement With A Global Payer Network

Sandoz signed a multi-year supply agreement with a global payer network to provide certified biosimilar products across its entire formulary network. The agreement was structured as a direct supply contract, not a joint venture or equity arrangement. The deal covers both adalimumab and ustekinumab biosimilar formats.
Signal: Signals established suppliers are securing
OCTOBER 2025

Celltrion Acquires A Regional Interchangeability Study Specialist

Celltrion completed the acquisition of a regional clinical bridging study technology specialist, adding interchangeability designation capability to its existing biosimilar portfolio. The transaction was a full acquisition, not a licensing or minority equity arrangement. The specialist brought clinical study technology Celltrion had previously lacked overall.
Signal: Signals established suppliers are consolid

What Drives Biosimilar Production Cost

Cell culture and purification inputs account for roughly 34% of production cost, sourced from specialized biological suppliers concentrated in the United States, Germany, and increasingly India. Regulatory approval and clinical bridging study costs add another 29%, while distribution and cold-chain logistics make up most of the remainder across supplier operations tracked here. Cell culture sourcing remains the single largest cost driver by far.
Cell culture media costs spiked in 2022 as broader biological supply chain disruption raised specialized fermentation input prices across nearly every biologic manufacturing category simultaneously. Amgen's 2022 annual disclosure cited elevated biological input costs as a direct pressure on biosimilar segment margins that year, pushing several suppliers toward extended production timelines until sourcing conditions eased gradually into 2023 across most regional markets overall each year.

Smaller regional suppliers carry the sharpest exposure, since they lack the purchase volume to negotiate long-term cell culture supply contracts that Amgen and Sandoz secure directly with specialized biological suppliers. Geographic exposure varies too: suppliers sourcing domestic biological inputs face lower cost volatility than those dependent on imported cell culture media, a gap that widens whenever regional prices spike against otherwise stable domestic supply structures overall.
psoriasis-biosimilars-market-cost-volatility-analysis-1787309664161

Lock Multi-Year Cell Culture Supply Agreements

Suppliers with sufficient purchase volume are negotiating multi-year cell culture media supply agreements directly with biological input manufacturers, trading pricing flexibility for guaranteed allocation during industry-wide shortages affecting the category each cycle overall each year This approach favors the largest suppliers, since minimum volume commitments required for favorable terms sit beyond smaller regional producers' reach.

Qualify Alternative Regional Biological Sourcing

Some suppliers now qualify alternative regional cell culture sourcing networks that reduce single-supplier dependency across multiple manufacturing lines rather than relying entirely on one biological input manufacturer, trading some cost optimization for improved flexibility each cycle overall Smaller suppliers, lacking dedicated sourcing staff, often lag behind larger competitors on this same work each cycle overall.

Build Regional Manufacturing Capacity Near Demand

Opening manufacturing facilities closer to major payer distribution networks, as several suppliers have done in India and China, cuts logistics cost and currency exposure even when core biological inputs still ship from concentrated regional suppliers each cycle Suppliers who delay this investment risk losing accounts to nearer competitors already operating locally each cycle overall.

Portfolio Architecture for Margin Defence

The portfolio splits into three tiers with clear margin separation. Volume-tier products, standard non-interchangeable biosimilars sold largely into price-sensitive commercial payer channels, compete hard and earn modestly. Premium certified products, covering interchangeable biosimilars meeting documented substitution eligibility specifications, earn considerably more because regulatory and payer contracting depth support pricing. Next-generation combination biosimilar and patient support platf
The tension here is common to specialty pharmaceutical businesses: volume commodity revenue funds the manufacturing scale premium products depend on, yet volume growth alone cannot fund the regulatory development next-generation solutions require. Suppliers leaning too heavily into premium positioning risk losing the manufacturing scale that makes market entry viable in price-sensitive commercial payer channels, while volume players cede premium specification entirely to diversified rivals.

High-value pools concentrate where interchangeability, payer contracting, and health system trust intersect: interchangeable and support-bundled products serving buyers willing to pay for verified, documented performance. That intersection is a minority of revenue globally but expanding quickly, which is why the next-generation tier grows fastest even while representing a modest volume share overall.

Volume / Commodity-Adjacent Tier

Standard non-interchangeable biosimilars sold largely into price-sensitive commercial payer and government formulary channels, competing directly against low-cost regional producers, where margins compress steadily each year overall across most producing regions worldwide.
Gross Margin: 20%-29%

Premium / Certified Tier

Interchangeable biosimilars meeting documented substitution eligibility specifications, sold to buyers willing to pay for regulatory depth and repeat contract renewal rates over successive cycles across most buyer categories tracked closely.
Gross Margin: 32%-42%

Sustainability / Regulatory / Next-Generation Tier

Combination biosimilar and patient support platforms representing the connected specialty pharmacy intelligence frontier, priced at a substantial premium justified by contracting infrastructure depth and expanding support scope. Few suppliers currently compete here, leaving considerable room for early leadership.
Gross Margin: 40%-52%
psoriasis-biosimilars-market-portfolio-architecture-1787309664656

High-value Sub-segments and Strategic Watch-out

Ustekinumab Biosimilars

The fastest-growing and highest-margin segment, expanding at 19.4% as recent patent expiration preference increasingly drives specification across new procurement programs, particularly among newer payer conversion launches nationwide, a pattern MMA expects to persist through the decade across most categories tracked nationwide overall each year each cycle.
Gross Margin: 40%-52%

Adalimumab Biosimilars

High value with strong growth as payer substitution increasingly drives specification, though overall expansion trails ustekinumab formats since this category has already absorbed its initial post-launch conversion wave each year across most markets tracked closely overall each year nationwide overall each cycle across most categories tracked closely.
Gross Margin: 32%-42%

Etanercept Biosimilars

The volume core by unit count, covering the bulk of standard demand across established biosimilar prescribing programs worldwide, generating steady but moderate margins as production becomes increasingly price-competitive each year across most categories overall each cycle across most categories tracked nationwide overall each year across most regions tracked.
Gross Margin: 20%-29%

Infliximab Biosimilars

The strategic watch-out, as newer subcutaneous biologic formulations increasingly reduce infusion-based infliximab prescribing volume wherever alternative administration routes are available, leaving this category's growth trailing even as overall market volume expands each year across most regional markets tracked closely each cycle overall each year nationwide.

How Biosimilar Demand Commits

Demand here commits through a payer formulary contracting cycle rather than a single point-of-sale purchase decision. A payer that selects a specific supplier's biosimilar for preferred formulary status typically commits to that relationship for the full multi-year contract cycle, since switching requires renegotiating rebate terms and revalidating supply continuity already built around the original supplier's contract each renewal cycle.
Adoption depth varies by payer type. Large national commercial and government payers adopt interchangeable biosimilars readily, given the cost-containment stakes that make documented substitution eligibility essential rather than optional across their formulary management programs. Smaller regional health plans adopt more cost-consciously, weighing biosimilar contracting complexity against a formulary budget that competes with tighter administrative margins overall. Specialty pharmacy networks occupy a distinct position, often prioritizing patient switch support over marginal cost differences between comparable products.

Younger pharmacy benefit management teams increasingly research published substitution and interchangeability certification data directly rather than relying entirely on manufacturer sales representatives that previous procurement generations depended on for sourcing guidance. That shift is pushing suppliers toward more transparent published clinical data and digital verification tools, even though long-term formulary contracting relationships remain the actual purchasing mechanism for most repeat national payer accounts today.
psoriasis-biosimilars-market-end-use-penetration-index-1787309665144

Where This Market Rewards Contracting Depth

These are among the four positions where our research anticipates prominent divergence between winners and laggards over the coming forecast period. Each is grounded in the demand model, the regulatory perimeter, and the announced capacity pipeline.
01 / INTERCHANGEABILITY REGULATORY STRATEGY

Winners will secure designation before payers demand it

Raw manufacturing cost alone no longer separates leading suppliers, since most competitors can eventually match a given biosimilar specification within a few product cycles. What actually separates winners is the speed of documented interchangeability designation reaching payers increasingly demanding proof ahead of large formulary commitments, because a technically capable biosimilar without documented substitution eligibility cannot win the procurement race that increasingly determines long-term payer loyalty. Suppliers building regulatory capability early, rather than waiting for competitive pressure, will out-earn comparable rivals over the coming decade overall.
02 / NATIONAL PAYER STRATEGY

Multi-year supply guarantees will decide account access

Supply reliability, not raw unit pricing alone, increasingly determines which suppliers can compete profitably as national payers standardize procurement around multi-year supply agreements across their entire formulary footprint. Suppliers who build guaranteed supply and continuity commitments early will capture account access that purely spot-market competitors cannot match, regardless of how competitive their underlying biosimilar pricing might otherwise be under normal procurement conditions. Those relying entirely on one-off contracts will find themselves increasingly unable to compete for the largest national payer accounts within this decade.
03 / PATIENT SWITCH INVESTMENT

Support programs will matter more than price alone

Suppliers still competing purely on raw pricing output are leaving durable revenue on the table that patient switch support and continuity assurance services already capture successfully for service-forward competitors across major national payer markets. These recurring revenue streams persist independent of the patent-cliff-cycle swings that otherwise define this market's uneven regional growth pattern tied to molecule expiration timing. Companies that build genuine patient support capability early will earn materially more per account relationship over a decade than those still selling only commodity biosimilar volume.
04 / REGIONAL MANUFACTURING FOOTPRINT

Local capacity will decide fast-growing Asian market access

Even where established European regulatory demand keeps growing steadily, long-term margin growth is increasingly shaped by how quickly suppliers secure regional manufacturing capacity across the fastest-growing South Asian biosimilar pathway, a shift individual firms cannot simply accelerate through pricing alone. Suppliers who invest early in regional biological sourcing and manufacturing capacity will capture positioning ahead of competitors still dependent entirely on legacy North American and European-only demand streams. This constraint will matter more to realized long-term margin than any single near-term pricing decision across every category tracked here.

Engagement Snapshot From the Field

A live engagement with an industry participant carrying material or product regulatory and market exposure ahead of a defining policy shift, showing how our research translates into a defensible multi-year portfolio strategy.
MARKET MINDS ADVISORY · CLIENT ENGAGEMENT SUMMARY
Psoriasis Biosimilars Producer Strategic Portfolio Review and Transition Roadmap 2026·Investment Scenario on Psoriasis Biosimilars Exposure Evaluation 2025-26
CLIENT PROFILE
A global commercial health plan approached MMA while evaluating whether to move its entire psoriasis biologic formulary to biosimilar-preferred status following the recent ustekinumab patent expiration and subsequent biosimilar launches. The client reported annual psoriasis biologic category spending near $210 million, with roughly 61% still flowing to originator products without biosimilar substitution (client-reported, unverified by MMA). Leadership sought an outside benchmark first.
STRATEGIC CHALLENGE
Leadership believed converting to biosimilar-preferred status would meaningfully reduce plan spending, but nobody had modeled the member disruption risk and rebate renegotiation timeline against the potential savings within the current fiscal planning cycle, leaving the decision stalled for months within the organization, leaving the initiative without clear executive sponsorship overall.
MMA APPROACH
MMA benchmarked commercial biosimilar offerings across four supplier partners against the client's existing formulary infrastructure, modeled member disruption and rebate renegotiation scenarios against comparable prior formulary conversions across the sector, and interviewed pharmacy directors at three peer health plans on real-world conversion criteria used nationwide each year overall each year.
KEY FINDINGS
  1. A phased molecule-by-molecule conversion plan building on the client's existing formulary infrastructure offered the clearest transition path, based on comparable prior conversion timelines (client-reported, unverified by MMA).
  2. Pharmacy director interviews revealed stronger member acceptance willingness than the client's own prior internal survey had indicated. This gap influenced the final conversion decision materially.
  3. The conversion timeline for the full psoriasis category ran only modestly longer than the client's standard annual formulary review cycle, given shared infrastructure across molecule categories.
  4. Two of the four supplier partners evaluated had secured meaningfully stronger national payer relationships after achieving interchangeability designation than non-designated regional peer suppliers had achieved.
CLIENT PROFILE
A global commercial health plan approached MMA while evaluating whether to move its entire psoriasis biologic formulary to biosimilar-preferred status following the recent ustekinumab patent expiration and subsequent biosimilar launches. The client reported annual psoriasis biologic category spending near $210 million, with roughly 61% still flowing to originator products without biosimilar substitution (client-reported, unverified by MMA). Leadership sought an outside benchmark first.
STRATEGIC CHALLENGE
Leadership believed converting to biosimilar-preferred status would meaningfully reduce plan spending, but nobody had modeled the member disruption risk and rebate renegotiation timeline against the potential savings within the current fiscal planning cycle, leaving the decision stalled for months within the organization, leaving the initiative without clear executive sponsorship overall.
MMA APPROACH
MMA benchmarked commercial biosimilar offerings across four supplier partners against the client's existing formulary infrastructure, modeled member disruption and rebate renegotiation scenarios against comparable prior formulary conversions across the sector, and interviewed pharmacy directors at three peer health plans on real-world conversion criteria used nationwide each year overall each year.
KEY FINDINGS
  1. A phased molecule-by-molecule conversion plan building on the client's existing formulary infrastructure offered the clearest transition path, based on comparable prior conversion timelines (client-reported, unverified by MMA).
  2. Pharmacy director interviews revealed stronger member acceptance willingness than the client's own prior internal survey had indicated. This gap influenced the final conversion decision materially.
  3. The conversion timeline for the full psoriasis category ran only modestly longer than the client's standard annual formulary review cycle, given shared infrastructure across molecule categories.
  4. Two of the four supplier partners evaluated had secured meaningfully stronger national payer relationships after achieving interchangeability designation than non-designated regional peer suppliers had achieved.
RECOMMENDED STRATEGY
Phase 1: Phase 1 (0 to 3 months): Finalize the phased molecule conversion plan with the selected supplier partners directly, confirming timelines directly. Phase 2: Phase 2 (3 to 8 months): Complete initial adalimumab conversion while maintaining originator access for ustekinumab company-wide overall company-wide overall. Phase 3: Phase 3 (8 to 14 months): Launch full category conversion, monitoring member disruption and savings closely throughout each phase overall.
OUTCOME
The client proceeded with the phased conversion plan and began supplier partner integration on schedule, tracking meaningfully faster than the originally projected timeline, with initial adalimumab conversion completed ahead of the internal target date. The client reported strong early savings realization ahead of the anticipated rollout expansion (client-reported, unverified by MMA).

Frequently Asked Questions

Foundational context covering the market sizes, CAGR, scope, country, region and competition that inform every finding below. This section is provided to cover basics and most often pre-purchase conversations, answered from the MMA Primary Research Dataset.

What is the current size of the Psoriasis Biosimilars Market?

The market stood at USD 2.8 billion in 2025, based on MMA Primary Research Dataset findings. Expanding payer substitution policy remains the largest driver of accelerating biosimilar conversion.

How large will the Psoriasis Biosimilars Market be by 2036?

MMA projects the market will reach USD 12.06 billion by 2036 under the base case scenario, representing roughly 3.77 times the 2026 opening value across the eleven-year forecast period.

What is the CAGR for the Psoriasis Biosimilars Market 2026 to 2036?

The base case CAGR is 14.2% annually. MMA's bull scenario reaches 15.5% while the bear scenario, reflecting originator rebate strategies, runs closer to 12.9% over the forecast period.

Which segment is growing fastest?

Ustekinumab biosimilars lead at 19.4% CAGR, roughly 1.37 times the overall market rate, as payers rapidly convert recently patent-expired Stelara volume into biosimilar alternatives nationwide.

Who are the major companies in the Psoriasis Biosimilars Market?

Amgen, Sandoz, Samsung Bioepis, Celltrion, and Biocon Biologics lead the market, together controlling an estimated 48% of global revenue on a consistent, comparable revenue basis.

Which country is growing fastest?

India posts the fastest national growth at 16.4% CAGR, driven by its expanding biosimilar manufacturing base and rising domestic production capacity. Domestic suppliers increasingly compete for export orders.

Report Segmentation Architecture

The full report scope spans multiple orthogonal segmentation dimensions, with cross-tabulated demand data provided for each dimension pair. Coverage extends further to regional breakdowns, trend trajectories, and the competitive detail needed to support segment-level decision-making.

By Originator Reference Molecule

  • Adalimumab Biosimilars
  • Ustekinumab Biosimilars
  • Etanercept Biosimilars
  • Infliximab Biosimilars

By End-Use Setting

  • Retail and Specialty Pharmacy
  • Hospital Outpatient Infusion Centers
  • Government Health Programs
  • Commercial Health Plans

By Commercial Dimension

  • Direct Payer Contracts
  • Pharmacy Benefit Manager Channels
  • National Formulary Agreements
  • Patient Switch Support Bundling

By Region

  • North America
  • Western Europe
  • East Asia
  • South Asia and Pacific
  • Latin America
  • Middle East and Africa
  • Eastern Europe

Scope, Methodology, and Coverage

Every figure in this report is reproducible from documented input assumptions. The scope below maps the historical period, the forecast horizon, the segmentation dimensions, and the countries covered, alongside the underlying primary and qualitative methodology.
Historical Period
2020 to 2025
Forecast Period
2026 to 2036
Base Year
2025 (USD billions; MMA Primary Research Dataset, August 2026)
Market Definition
The psoriasis biosimilars market covers biosimilar versions of adalimumab, ustekinumab, etanercept, infliximab, and related biologic therapies approved for moderate-to-severe plaque psoriasis and psoriatic arthritis. It excludes originator biologic products still under patent protection, small-molecule systemic therapies, and topical psoriasis treatments covered under separate market reports.
Quantitative Units
USD billions (current prices); units shipped where applicable
Segmentation Dimensions
By Originator Reference Molecule; By End-Use Setting; By Commercial Dimension; By Region
Regions Covered
North America, Western Europe, East Asia, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe
Countries Covered
USA, Canada, China, Japan, South Korea, India, Australia, Singapore, Germany, France, UK, Netherlands, Nordics, Italy, Spain, Brazil, Mexico, UAE, Saudi Arabia, South Africa, Poland, Czech Republic, Hungary, Romania, Russia, and additional markets relevant to this sector
Key Companies Profiled
Amgen Inc., Sandoz Group AG, Samsung Bioepis Co., Ltd., Celltrion, Inc., Biocon Biologics Limited, Teva Pharmaceutical Industries Ltd., Coherus BioSciences, Inc., Fresenius Kabi AG, Alvotech, Boehringer Ingelheim, Viatris Inc., Pfizer Inc., Formycon AG, Dr. Reddy's Laboratories Ltd., Bio-Thera Solutions, Ltd., Accord Healthcare Limited, Organon & Co., Lupin Limited, Shanghai Henlius Biotech, Inc., Prestige Biopharma Limited
Quantitative Methodology
Primary survey, n=3,800 respondents, Q4 2025, six countries; demand-side model with trade association cross-validation
Qualitative Methodology
47 expert interviews, Q4 2025; applied to validate demand model assumptions, identify emerging dynamics, and assess competitive positioning
Report Format
PDF and XLSX data workbook (Word format preview document)
Publisher
Market Minds Advisory
Report Code
MMA-2026-HLT-171
Published
August 2026
Contact
sales@marketmindsadvisory.com | www.marketmindsadvisory.com

Purchase the full Psoriasis Biosimilars Market Report (2026 to 2036).

The full MMA Psoriasis Biosimilars report sizes the market across four molecule categories, four end-use setting categories, four commercial channels, and seven regions through 2036. It profiles 20 participants on a consistent revenue basis, scoring the top five on interchangeability depth, payer contracting breadth, and supply reliability. Scenario models quantify how payer substitution policy, national formulary standardization, and India's manufacturing advantage move both demand and realizable pricing. The report also includes biological-input-cost modelling by molecule, a regional substitution policy tracker, and a competitive benchmarking tool built for market access strategy, payer procurement, and investor due diligence teams.
Four-category molecule segmentation with regional cross-tabulation
Interchangeability and substitution policy tracker across twelve major markets
Competitive benchmarking on consistent revenue basis
Biological-input-cost modelling by molecule and region
Scenario models for ustekinumab and adalimumab demand
India manufacturing advantage analysis by supplier

Built For The People Who Decide

From boardroom strategy to bench-side execution, this report is read cover-to-cover by leaders shaping the next decade of their industry, turning demand scenarios, market dynamics and valuation benchmarks into decisions.
CXOs/ Presidents/ VPs/ Managers
M&A and Corporate Development
Strategy Teams and R&D Heads
Procurement and Product Directors
Regulatory and Compliance Leaders
Investor Relations and Equity Analysts